Medscape is available in 5 Language Editions – Choose your Edition here.


Malignant Tumors of the Temporal Bone Treatment & Management

  • Author: Stephanie A Moody Antonio, MD; Chief Editor: Arlen D Meyers, MD, MBA  more...
Updated: Feb 25, 2016

Medical Therapy

Primary radiation is ineffective for curative treatment. In the most extreme cases in which contraindications to surgery are serious deterrents to surgery, palliative radiation and chemotherapy may be offered. The literature supports a beneficial effect of adjunctive radiation on survival, but no well-controlled studies have been performed. Postoperative radiation treatment may be indicated in advanced disease. Most authors advocate full course postoperative radiation to stage T3 or T4 tumors as defined by the University of Pittsburgh staging system. Some authors also recommend radiation for T2 disease.[14]

The literature supports a beneficial effect of postoperative radiation on survival.[1, 6] The temporal bone and neck should be treated with 50-60 Gy for tumors staged T3 and T4. Radiation may also be indicated for smaller lesions.

Preoperative chemotherapy was reviewed by Nakagawa et al in a retrospective series of patients treated with preoperative chemoradiation or with chemoradiation alone).[15] Four of 8 patients treated with chemoradiation (5-Flourouracil or a fluoropyrimidine complex during external beam radiation with a dose of 40Gy), followed by chemotherapy in one case, were free of disease at 24-47 months. Pemberton et al reported 53% cancer-specific survival of 123 patients treated with radiotherapy alone (55 Gy).[16]

Based on a retrospective study and literature review of patients with temporal bone paragangliomas, Prasad et al recommended that elderly patients with advanced forms of these tumors be managed with a wait-and-scan approach, with radiotherapy reserved for the treatment of fast-growing tumors. In the study, among patients with class C or D tumors who underwent wait-and-scan management, the investigators found that the tumor remained stable in 22 of 24 patients who were followed up for less than 3 years and that the paraganglioma remained stable or regressed in 10 of 12 patients who were followed up for 3-5 years. In addition, the tumor remained stable or regressed in five of 11 patients who were followed up for more than 5 years.[17]

A literature review, Prasad and colleagues stated, revealed no conclusive evidence that radiotherapy is an effective primary modality for the treatment of either class C or D temporal bone paragangliomas.[17]


Surgical Therapy

In general, all patients who are medically able should undergo surgical treatment. The optimal surgery removes all of the cancer en bloc because positive margins are associated with poor survival rates. The resection procedures that can be performed for the temporal bone include a modified lateral temporal bone resection, lateral temporal bone resection, subtotal temporal bone resection, and total temporal bone resection. The specific procedures and nomenclature vary among surgeons. Adjunctive surgical procedures, including neck dissection, parotidectomy, and craniotomy, should be performed when indicated. Advanced tumors with intracranial invasion have a grave prognosis, and treatment should probably be limited to palliation with less extensive (and less morbid) surgical procedures.


Preoperative Details

Determination of tumor stage and medical status assists the surgeon in surgical planning. The goal should be complete tumor removal with preservation of CNs and other vital structures whenever possible. Preoperative planning includes mapping of disease extent by both clinical and radiographic evaluation. Tumor encroachment to the region of the internal carotid artery, sigmoid sinus, or jugular vein requires further investigation such as balloon test occlusion with xenon/CT scan (demonstrating the integrity of the contralateral cerebral artery) or angiography with venous phase (to determine dominance of the cerebral outflow). Consultation with a neurosurgeon may be necessary if involvement of the dura is suspected. The patient's medical status plays a major role in his or her tolerance of a long surgical procedure, postoperative recovery, healing, and postoperative rehabilitation.


Intraoperative Details

Management of the primary site

Hirsch and Chang have described the operative procedures in detail and the indications based on the location and stage of the tumor.[18] Medina (1990) described several modifications of the lateral temporal bone dissection (LTBR) based on the location of disease.[19]

A modified LTBR removes the EAC and leaves the uninvolved tympanic membrane intact. This type of resection is appropriate for tumors originating in the concha without involvement of the EAC.

The LTBR includes resection of the EAC, tympanic membrane, malleus, and incus. The boundaries are the middle ear cavity and stapes medially, the mastoid cavity posteriorly, the epitympanum and zygomatic root superiorly, the temporomandibular joint (TMJ) capsule anteriorly, and the medial tympanic ring or infratemporal fossa (ITF) inferiorly. The lateral margin depends on the extent of spread. The otic capsule and facial nerve are preserved. The LTBR is appropriate for T1 and T2 tumors.

The LTBR begins with a long, postauricular incision extending from the temporal fossa into the neck. If the pinna is to be preserved, a second incision is made within the concha lateral to the lesion. If the pinna is to be resected, a preauricular incision is incorporated to the postauricular incision allowing the pinna and surrounding skin to be included in the specimen. A cortical mastoidectomy is performed and the facial nerve identified. Bone removal is extended into the zygomatic root and to the digastric ridge. An extended facial recess is made, and the incudostapedial joint is separated. The facial recess is continued inferiorly and anteriorly lateral to the facial nerve, but medial to the annulus, until the specimen is attached only at the anterior canal bony wall at the level of the temporomandibular capsule. An osteotome is used to separate the bony specimen. The parotidectomy is performed en bloc.

A subtotal temporal bone resection (STBR) is performed when invasion medial to the tympanic membrane or into the mastoid (T3 disease) is evident. In this case, the medial margin may be obtained in a piecemeal fashion, usually with a drill. The specimen includes the LTBR with additional dissection of the otic capsule and the medial bony wall of the middle ear and mastoid. The margins of resection are the sigmoid sinus and posterior fossa dura posteriorly, middle fossa dura superiorly, internal carotid artery anteriorly, jugular bulb inferiorly, and petrous apex medially. Based on the extent of tumor spread, dissection may include the condyle of the mandible, the facial nerve, dura, sigmoid sinus, and contents of the infratemporal fossa. The carotid artery is skeletonized and becomes the medial margin.

Tumor involvement of the jugular bulb requires ligation of the inferior jugular vein and proximal control of the sigmoid sinus. The facial nerve is traditionally sacrificed, with the proximal margin taken in the labyrinthine or internal auditory canal segment. However, the surgeon may elect to preserve the nerve if no indication of nerve involvement exists. The medial extent of dissection at the level of the otic capsule depends on the depth of involvement and is done piecemeal. Tumor extension into the protympanum, eustachian tube, or carotid artery is addressed with an infratemporal fossa dissection. The temporalis muscle is reflected and the zygomatic arch removed. The mandibular condyle is resected. The dissection proceeds based on the extent of disease but may include identification of the pterygoid plate, the mandibular nerve (V3), and the horizontal carotid artery and may include a temporal craniotomy.

A total TBR can be used to address T4 disease. However, this procedure is associated with significant morbidity and may not significantly improve survival in these cases of advanced disease. The total TBR includes the STBR with the additional resection of the petrous apex. The internal carotid artery may be isolated, mobilized, and preserved or resected. The sigmoid sinus, jugular vein, carotid artery, dura and CNs are removed as indicated by the extent of the tumor.

Management of the parotid and temporomandibular joint

The intraparotid lymph nodes are a first echelon drainage site for cancers of the EAC and middle ear. An adequate anterior margin for the temporal bone resection routinely involves resection of the parotid gland, temporomandibular joint, and condyle. Resection of these soft tissues will also address minimal soft tissue extension beyond the temporal bone. Ideally, this is performed en bloc with the temporal bone. A superficial parotidectomy is performed with preservation of the facial nerve for T1 and T2 tumors. When the facial nerve is resected for more advanced lesions, a total parotidectomy may be performed.

Management of the neck

Although metastasis to the neck is uncommon in limited cancers of the temporal bone, neck dissections are routinely performed. With more extensive cancers, dissection of the neck offers staging and provides control of the great vessels and exposure to the skull base. However, the presence of metastasis is associated with a poor prognosis, and neck dissection does not improve survival.[6, 1]

Management of the dura and brain

Although involvement of the dura and brain portend for a poor prognosis, an aggressive approach includes resection of the dura and a small volume of the temporal lobe with a healthy margin.


Facial nerve grafting is usually not performed in the presence of a malignant lesion. Management of facial nerve paralysis may include CN XII to VII grafting, cross facial grafting, and static procedures. Extensive resections may result in large soft tissue defects. A temporalis muscle flap can be used to fill small to medium defects. The pedicled myocutaneous trapezius flap is an excellent option for reconstruction of the soft tissue and skin defect. The pectoralis flap has limited distant reach to the resected margin. The rectus abdominus free flap and radial forearm flap are particularly suited for the area. Dural defects should be repaired primarily or with graft reconstruction.


Postoperative Details

Postoperative care consists of monitoring wound complications, flap viability, intracranial complications, and complications of CN deficits. If the dura was resected and repaired, the wound should be observed for a cerebrospinal fluid leak. Supportive care for dizziness, nausea, and vertigo is needed when the otic capsule is entered during the resection. Eye care should be instituted if postoperative facial paralysis develops or if the facial nerve is resected. Resection of CN X requires swallowing and vocal fold rehabilitation and observation for aspiration or airway complications. If the temporomandibular joint was removed, the mandible should be mobilized early to prevent contralateral dysfunction.



Complications of treatment depend on the extent of resection and the use of adjunctive radiation. Postoperative hearing loss, facial nerve paralysis, vertigo, and other CN deficits (eg, CN V, VII, VIII, IX, X, XI) may occur. Dural resection may predispose to cerebral spinal fluid leaks, meningitis, or intracranial complications. Significant complications can result from trauma to or resection of the carotid artery. Radiation has known complications of fibrosis of soft tissues, destruction of salivary gland tissue, osteoradionecrosis of the temporal bone, and possibly central nervous system effects if the field of radiation extends to intracranial tissues.


Outcome and Prognosis

Prognosis is related to the primary site, the histologic type, and treatment.[20] The outcome of treatment for early stage tumors is favorable, with most series reporting an 80-100% survival rate. Later stage cancers after adequate surgery and radiation treatment have a survival between 50% and 80%. Advanced lesions have a poor prognosis despite aggressive treatment, with 2-year survival of 0-40%.[6, 1] Salvage surgery after an incomplete resection is associated with a poorer prognosis compared to a definitive procedure in an undisrupted field.[1] A mastoidectomy or limited excision performed by an outside institution prior to referral complicates preoperative assessment and staging, disrupts margins, and forces the surgeon to operate in an inflamed field with interrupted landmarks. Positive margins, nodal disease, dural involvement, and advanced disease are associated with poorer survival.[6, 1]

A study by Marioni et al indicated that in patients with advanced, aggressive temporal bone squamous cell carcinoma, the risk for tumor recurrence after postoperative radiotherapy is increased in those with a primary tumor classification of 4, a pathologic grade of 2 or 3, and dura mater involvement.[21]


Future and Controversies

The optimal management of temporal bone cancer remains unclear because of continued debate regarding staging, the utility of preoperative radiographic evaluation, the extent and nomenclature of surgical procedures, and the use of adjuvant radiation. The limited number of cases of temporal bone malignancies at each individual institution precludes definitive conclusions regarding the optimum protocol for management. The future of improved treatment strategies lies in a multi-institutional effort to adopt a staging system and develop prospective trials.

Contributor Information and Disclosures

Stephanie A Moody Antonio, MD Associate Professor, Department of Otolaryngology-Head and Neck Surgery, Eastern Virginia Medical School

Stephanie A Moody Antonio, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, Virginia Society of Otolaryngology-Head and Neck Surgery, American Neurotology Society, American Medical Association

Disclosure: Nothing to disclose.


Barry E Hirsch, MD Professor, Department of Otolaryngology, Director, Division of Otology/Neurotology, University of Pittsburgh School of Medicine

Barry E Hirsch, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American Neurotology Society, American College of Surgeons, American Otological Society, Phi Beta Kappa

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Erik Kass, MD Chief, Department of Clinical Otolaryngology, Associates in Otolaryngology of Northern Virginia

Erik Kass, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Medical Association, American Association for Cancer Research, American Rhinologic Society

Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan;RxRevu;SymbiaAllergySolutions<br/>Received income in an amount equal to or greater than $250 from: Symbia<br/>Received from Allergy Solutions, Inc for board membership; Received honoraria from RxRevu for chief medical editor; Received salary from Medvoy for founder and president; Received consulting fee from Corvectra for senior medical advisor; Received ownership interest from Cerescan for consulting; Received consulting fee from Essiahealth for advisor; Received consulting fee from Carespan for advisor; Received consulting fee from Covidien for consulting.

Additional Contributors

B Viswanatha, DO, MBBS, PhD, MS, FACS Professor of Otolaryngology (ENT), Sri Venkateshwara ENT Institute, Victoria Hospital, Bangalore Medical College and Research Institute, India

B Viswanatha, DO, MBBS, PhD, MS, FACS is a member of the following medical societies: Indian Medical Association, Indian Society of Otology, Association of Otolaryngologists of India

Disclosure: Nothing to disclose.

  1. Moffat DA, Wagstaff SA, Hardy DG. The outcome of radical surgery and postoperative radiotherapy for squamous carcinoma of the temporal bone. Laryngoscope. 2005 Feb. 115(2):341-7. [Medline].

  2. Keereweer S, Metselaar RM, Dammers R, Hardillo JA. Chronic serous otitis media as a manifestation of temporal meningioma. ORL J Otorhinolaryngol Relat Spec. 2011. 73(5):287-90. [Medline].

  3. Jin YT, Tsai ST, Li C, Chang KC, Yan JJ, Chao WY, et al. Prevalence of human papillomavirus in middle ear carcinoma associated with chronic otitis media. Am J Pathol. 1997 Apr. 150(4):1327-33. [Medline].

  4. Lim LH, Goh YH, Chan YM, Chong VF, Low WK. Malignancy of the temporal bone and external auditory canal. Otolaryngol Head Neck Surg. 2000 Jun. 122(6):882-6. [Medline].

  5. Leonetti JP, Smith PG, Kletzker GR, Izquierdo R. Invasion patterns of advanced temporal bone malignancies. Am J Otol. 1996 May. 17(3):438-42. [Medline].

  6. Moody SA, Hirsch BE, Myers EN. Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system. Am J Otol. 2000 Jul. 21(4):582-8. [Medline].

  7. Choi JY, Choi EC, Lee HK, Yoo JB, Kim SG, Lee WS. Mode of parotid involvement in external auditory canal carcinoma. J Laryngol Otol. 2003 Dec. 117(12):951-4. [Medline].

  8. Arriaga M, Curtin H, Takahashi H, Hirsch BE, Kamerer DB. Staging proposal for external auditory meatus carcinoma based on preoperative clinical examination and computed tomography findings. Ann Otol Rhinol Laryngol. 1990 Sep. 99(9 Pt 1):714-21. [Medline].

  9. Austin JR, Stewart KL, Fawzi N. Squamous cell carcinoma of the external auditory canal. Therapeutic prognosis based on a proposed staging system. Arch Otolaryngol Head Neck Surg. 1994 Nov. 120(11):1228-32. [Medline].

  10. Zhang B, Tu G, Xu G, Tang P, Hu Y. Squamous cell carcinoma of temporal bone: reported on 33 patients. Head Neck. 1999 Aug. 21(5):461-6. [Medline].

  11. Gillespie MB, Francis HW, Chee N, Eisele DW. Squamous cell carcinoma of the temporal bone: a radiographic-pathologic correlation. Arch Otolaryngol Head Neck Surg. 2001 Jul. 127(7):803-7. [Medline].

  12. Gaudet JE, Walvekar RR, Arriaga MA, Dileo MD, Nuss DW, Pou AM, et al. Applicability of the pittsburgh staging system for advanced cutaneous malignancy of the temporal bone. Skull Base. 2010 Nov. 20(6):409-14. [Medline]. [Full Text].

  13. Nyrop M, Grontved A. Cancer of the external auditory canal. Arch Otolaryngol Head Neck Surg. 2002 Jul. 128(7):834-7. [Medline].

  14. Kunst H, Lavieille JP, Marres H. Squamous cell carcinoma of the temporal bone: results and management. Otol Neurotol. 2008 Jun. 29(4):549-52. [Medline].

  15. Nakagawa T, Kumamoto Y, Natori Y, et al. Squamous cell carcinoma of the external auditory canal and middle ear: an operation combined with preoperative chemoradiotherapy and a free surgical margin. Otol Neurotol. 2006 Feb. 27(2):242-8; discussion 249. [Medline].

  16. Pemberton LS, Swindell R, Sykes AJ. Primary radical radiotherapy for squamous cell carcinoma of the middle ear and external auditory cana--an historical series. Clin Oncol (R Coll Radiol). 2006 Jun. 18(5):390-4. [Medline].

  17. Prasad SC, Mimoune HA, D'Orazio F, et al. The role of wait-and-scan and the efficacy of radiotherapy in the treatment of temporal bone paragangliomas. Otol Neurotol. 2014 Jun. 35(5):922-31. [Medline].

  18. Hirsch BE, Chang CYJ. Carcinoma of the temporal bone. Myers EN, ed. Operative Otolaryngology Head and Neck Surgery. Philadelphia, Pa: WB Saunders; 1997. 1434-1458.

  19. Medina JE, Park AO, Neely JG, Britton BH. Lateral temporal bone resections. Am J Surg. 1990 Oct. 160(4):427-33. [Medline].

  20. Morris LG, Mehra S, Shah JP, Bilsky MH, Selesnick SH, Kraus DH. Predictors of survival and recurrence after temporal bone resection for cancer. Head Neck. 2011 Sep 23. [Medline].

  21. Marioni G, Zanoletti E, Giacomelli L, Braggio L, Martini A, Mazzoni A. Clinical and pathological parameters prognostic for increased risk of recurrence after postoperative radiotherapy for temporal bone carcinoma. Head Neck. 2015 Sep 8. [Medline].

  22. Conley JJ, Novack AJ. The surgical treatment of malignant tumors of the ear and temporal bone. Part I. AMA Arch Otolaryngol. 1960 Apr. 71:635-52. [Medline].

  23. Hirsch BE, Myers EN, Moody SA. Malignant tumors of the temporal bone. Laercio O, Selaimen S, eds. Otologia Clinia e Cirurgica. Revinter, Tijuca: 2000. 319-329.

  24. Parsons H, Lewis JS. Subtotal resection of the temporal bone for cancer of the ear. Cancer. 1954 Sep. 7(5):995-1001. [Medline].

Coronal image that represents the following potential routes of spread of temporal bone cancer: 1) Anteriorly into the soft tissues of the temporomandibular joint and parotid through the fissures of Santorini. 2) Laterally via the soft tissue and cartilage of the external auditory canal to the concha and pinna. 3) Medially through the tympanic membrane to the middle ear, inner ear, and mastoid. 4) Posteriorly into the mastoid, epitympanum, and middle fossa. 5) Spread can continue through the Eustachian tube to the infratemporal fossa. 6) Spread through the round window, oval window, or facial nerve into the internal auditory canal and cerebellopontine angle. 7) Along the facial nerve through the mastoid and into the stylomastoid foramen and beyond. 8) Via the mastoid into posterior fossa 9) Along structures of the skull base, including the carotid, jugular bulb, and clivus.
Axial image that shows the spread of temporal bone cancer.
Axial T1 MRI with gadolinium of right T4 squamous cell carcinoma.
Axial T1 precontrast image of the same patient from Image 3.
Axial CT scan of the same patient from Image 3 with T4 squamous cell carcinoma.
Axial CT scan of a patient with recurrent basil cell carcinoma of the pinna, spread to the left inferior temporal bone.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.